Vagus Nerve Stimulation for Heart Failure: What Clinical Trials Show
Introduction: Autonomic Dysfunction in Heart Failure
Heart failure (HF) affects approximately 64 million people globally and remains a leading cause of hospitalisation and mortality in the developed world, despite significant advances in pharmacological and device-based therapies (Savarese & Lund, 2017). A defining feature of HF — and one that is increasingly recognised as both a consequence and a driver of disease progression — is autonomic dysfunction.
In healthy individuals, the autonomic nervous system maintains a dynamic balance between sympathetic ("fight or flight") and parasympathetic ("rest and digest") activity. The vagus nerve is the primary conduit of parasympathetic input to the heart, slowing heart rate, reducing cardiac workload, and exerting anti-inflammatory and anti-arrhythmic effects. In heart failure, this balance is profoundly disrupted: sympathetic activity is chronically elevated while parasympathetic (vagal) tone is markedly reduced.
This sympathovagal imbalance is not merely a biomarker of disease severity — it actively contributes to disease progression through several mechanisms. Chronic sympathetic activation promotes cardiac remodelling (maladaptive structural changes in the heart), increases the risk of arrhythmias, elevates inflammatory mediators, and impairs the heart's ability to respond to changing demands. Reduced vagal tone, meanwhile, removes a protective brake that normally counteracts these processes.
It was this understanding that led researchers to hypothesise that vagus nerve stimulation (VNS) — by directly augmenting parasympathetic tone — could restore autonomic balance and thereby slow or reverse the progression of heart failure.
The Rationale for VNS in Heart Failure
Restoring Sympathovagal Balance
The central therapeutic rationale for VNS in heart failure is straightforward: if autonomic imbalance drives disease progression, then restoring balance — specifically by increasing vagal tone — should be therapeutic. This concept is supported by decades of research linking impaired heart rate variability (HRV), a surrogate marker of vagal tone, to worse outcomes in heart failure patients.
Reduced HRV is one of the strongest independent predictors of mortality in heart failure (Nolan et al., 1998). Conversely, interventions that improve vagal tone — including exercise training, cardiac rehabilitation, and beta-blocker therapy — are associated with improved outcomes. VNS offers a more direct approach to augmenting vagal activity than any of these strategies.
Anti-Inflammatory Effects
Heart failure is characterised by chronic low-grade systemic inflammation, with elevated levels of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. These cytokines contribute to myocardial depression, endothelial dysfunction, and progressive cardiac remodelling. The cholinergic anti-inflammatory pathway — activated by vagal stimulation — suppresses the production of these cytokines through the release of acetylcholine acting on alpha-7 nicotinic receptors on macrophages (Tracey, 2002).
This anti-inflammatory mechanism provides a second rationale for VNS in heart failure, independent of its autonomic effects. By reducing the inflammatory burden that perpetuates cardiac damage, VNS could potentially influence the underlying disease process rather than merely treating symptoms.
Anti-Arrhythmic Properties
Sudden cardiac death due to ventricular arrhythmias accounts for approximately 50% of mortality in heart failure. Vagal stimulation has well-documented anti-arrhythmic properties, including prolongation of the refractory period, stabilisation of cardiac electrical activity, and suppression of triggered arrhythmias. While this has not been a primary endpoint in most VNS trials for heart failure, it represents an additional potential benefit of autonomic rebalancing.
Preclinical Evidence
Animal studies provided strong support for VNS in heart failure before clinical trials began. In canine models of HF induced by rapid pacing, Li et al. (2004) demonstrated that VNS significantly improved left ventricular function, reduced heart rate, and suppressed inflammatory markers compared to untreated controls. Subsequent studies by Zhang et al. (2009) and Hamann et al. (2013) confirmed and extended these findings, showing that VNS reduced cardiac fibrosis, improved ventricular remodelling, and enhanced survival in animal models of heart failure.
The Clinical Trials
ANTHEM-HF: Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure
ANTHEM-HF (Premchand et al., 2014) was a prospective, open-label feasibility study that enrolled 60 patients with symptomatic heart failure (NYHA Class II-III) and reduced ejection fraction (LVEF ≤40%). Patients were implanted with a VNS system and followed for six months.
The results were notable:
- Left ventricular ejection fraction (LVEF) improved significantly, with a mean increase of 4.5 percentage points — a clinically meaningful change in a population where LVEF is a key prognostic marker
- Heart rate variability improved substantially, confirming the intended autonomic effect of the therapy
- Six-minute walk distance increased, indicating improved functional capacity
- Quality of life scores improved significantly on the Minnesota Living with Heart Failure Questionnaire
- NYHA functional class improved in the majority of patients
Premchand et al. (2016) reported 12-month follow-up data from ANTHEM-HF, demonstrating that the improvements in LVEF, HRV, and functional capacity were sustained or continued to improve over the longer follow-up period. The sustained improvement in LVEF was particularly encouraging, as it suggested that VNS was influencing cardiac remodelling rather than simply producing a transient haemodynamic effect.
A distinctive feature of ANTHEM-HF was that VNS was delivered to both left and right cervical vagus nerves (different patients received different sides), and benefits were observed regardless of the side stimulated. This was significant because it suggested that the therapeutic effects of VNS in heart failure may not require targeting the right vagus nerve (which has more direct cardiac innervation) specifically.
INOVATE-HF: INcrease Of VAgal TonE in Heart Failure
INOVATE-HF (Gold et al., 2016) was the largest and most rigorous trial of VNS for heart failure — a randomised, open-label study that enrolled 707 patients with NYHA Class III heart failure and LVEF ≤40%. Patients were randomised 3:2 to receive VNS plus optimal medical therapy (OMT) or OMT alone. The primary endpoint was a composite of all-cause mortality and heart failure events over a median follow-up of 16 months.
The trial did not meet its primary endpoint: there was no significant difference between the VNS and control groups in the composite of death or heart failure events (hazard ratio 0.96, 95% CI 0.74–1.25, p = 0.77). The trial was stopped early for futility based on a pre-specified interim analysis.
However, several secondary findings merit consideration:
- Heart rate reduction was minimal (approximately 1 beat per minute), suggesting that the delivered stimulation intensity may have been insufficient to achieve adequate vagal activation
- Subgroup analyses suggested potential benefit in patients who achieved a greater degree of heart rate reduction, consistent with the hypothesis that a physiological response to stimulation (as a marker of adequate vagal engagement) is necessary for therapeutic effect
- Quality of life measures showed trends toward improvement in the VNS group
The INOVATE-HF results generated substantial debate about whether the negative outcome reflected a true failure of the VNS concept in heart failure, or whether it was attributable to inadequate stimulation dosing. The device used in INOVATE-HF (CardioFit, BioControl Medical) delivered stimulation synchronised to the cardiac cycle and titrated to a pre-specified heart rate reduction target. Critics argued that the stimulation was insufficient — that patients were not receiving a large enough "dose" of vagal activation to produce the biological effects demonstrated in preclinical studies and in ANTHEM-HF, which used a different device and stimulation approach.
NECTAR-HF: Neural Cardiac Therapy for Heart Failure
NECTAR-HF (Zannad et al., 2015) was a randomised, sham-controlled trial of VNS in 96 patients with symptomatic heart failure and reduced ejection fraction. Patients received either active VNS or sham stimulation (device implanted but not activated) over six months.
Like INOVATE-HF, NECTAR-HF did not meet its primary endpoint: there was no significant difference in left ventricular end-systolic diameter between the active and sham groups. Secondary endpoints, including LVEF and NT-proBNP (a biomarker of heart failure severity), also showed no significant differences. However, quality of life measures improved significantly in the active VNS group compared to sham — suggesting that VNS may have had effects on symptoms that were not captured by the cardiac structural and biomarker endpoints.
An important observation from NECTAR-HF was that, like INOVATE-HF, the level of heart rate reduction achieved was modest, again raising questions about whether the stimulation intensity was sufficient. De Ferrari et al. (2017) subsequently published analyses suggesting that the stimulation parameters used in NECTAR-HF may not have been optimal for engaging the therapeutic mechanisms demonstrated in preclinical studies.
Lessons from the Trials: The Dosing Question
The divergent results of ANTHEM-HF (positive signals), INOVATE-HF (negative primary endpoint), and NECTAR-HF (negative primary endpoint but improved quality of life) have been extensively analysed. A consensus has emerged that the critical variable may be stimulation dose — the degree to which VNS actually engages vagal efferent and afferent pathways in a given patient.
De Ferrari & Bhatt (2017) argued that VNS for heart failure should be conceptualised similarly to pharmacotherapy: the drug must reach a therapeutic dose to be effective. In the case of VNS, a "therapeutic dose" would be stimulation sufficient to produce measurable physiological effects — primarily heart rate reduction and improved HRV — as evidence that vagal pathways are being meaningfully activated.
ANTHEM-HF, which used a different stimulation paradigm (Cyberonics/LivaNova device with continuous rather than cardiac-cycle-synchronised stimulation), achieved greater heart rate reductions and HRV improvements than INOVATE-HF or NECTAR-HF, potentially explaining its more positive results.
This dosing hypothesis has informed the design of the next generation of VNS trials for heart failure, including ANTHEM-HFrEF (NCT03425422), a pivotal randomised controlled trial specifically designed to test whether VNS delivered at adequate intensity — as confirmed by physiological markers of vagal engagement — can improve outcomes in heart failure with reduced ejection fraction.
Non-Invasive Approaches: taVNS for Heart Failure
Transcutaneous Auricular VNS
Given the challenges of surgical implantation, researchers have begun investigating non-invasive transcutaneous auricular VNS (taVNS) for heart failure. The appeal is clear: if taVNS can deliver sufficient vagal activation to produce the autonomic and anti-inflammatory effects demonstrated in preclinical studies, it could provide a scalable and accessible therapy.
Stavrakis et al. (2015) conducted a study examining low-level tragus stimulation (a form of taVNS) in patients undergoing cardiac surgery, demonstrating reduced atrial fibrillation burden and suppressed inflammatory cytokines. While not directly studying heart failure, this work established that taVNS could produce measurable cardiac autonomic and anti-inflammatory effects in humans.
Wang et al. (2019) investigated taVNS in patients with heart failure with preserved ejection fraction (HFpEF) — a subtype with no proven therapies beyond diuretics. The study found improvements in diastolic function parameters and reductions in inflammatory markers, suggesting that taVNS may influence the pathophysiology of HFpEF. However, the study was small and uncontrolled.
Zhou et al. (2022) conducted a systematic review of non-invasive VNS for cardiac conditions and concluded that while the evidence was promising, larger and more rigorous trials were needed before clinical recommendations could be made.
Mechanisms: How VNS May Benefit the Failing Heart
The clinical trial evidence, combined with extensive preclinical data, supports several complementary mechanisms through which VNS may benefit heart failure patients:
Autonomic Rebalancing
The primary mechanism is the direct augmentation of parasympathetic tone and reduction of sympathetic hyperactivity. This produces measurable physiological effects including heart rate reduction, improved HRV, and enhanced baroreflex sensitivity — all of which are associated with improved prognosis in heart failure.
Anti-Inflammatory Effects
VNS suppresses the production of pro-inflammatory cytokines through the cholinergic anti-inflammatory pathway. In heart failure, chronic inflammation contributes to myocardial depression, fibrosis, and progressive remodelling. By reducing this inflammatory burden, VNS may slow disease progression.
Reverse Cardiac Remodelling
The improvement in LVEF observed in ANTHEM-HF and the reduction in cardiac fibrosis seen in preclinical studies suggest that VNS may promote reverse remodelling — the restoration of more normal cardiac structure and function. This could occur through reduced inflammatory signalling, improved neurohormonal balance, and direct parasympathetic effects on cardiac myocytes.
Nitric Oxide Signalling
Vagal activation stimulates the release of nitric oxide (NO) from the endothelium, improving vascular function and reducing afterload (the resistance the heart pumps against). In heart failure, endothelial dysfunction and impaired NO signalling contribute to exercise intolerance and disease progression.
Future Directions
The field of VNS for heart failure is at a critical juncture. The key developments to watch include:
- ANTHEM-HFrEF pivotal trial — This large-scale RCT, designed with the dosing lessons of previous trials in mind, will provide the most definitive evidence to date on whether VNS can improve outcomes in heart failure with reduced ejection fraction
- Optimised stimulation parameters — Research into optimal frequency, intensity, and timing of VNS delivery, including whether continuous or intermittent stimulation is more effective
- HFpEF applications — Heart failure with preserved ejection fraction remains a condition with limited treatment options, and the anti-inflammatory and autonomic effects of VNS may be particularly relevant to this subtype
- taVNS as maintenance therapy — Exploring whether non-invasive taVNS could serve as a long-term maintenance therapy for heart failure, either alone or in combination with standard pharmacotherapy
- Biomarker-guided dosing — Using real-time HRV monitoring to titrate VNS intensity and ensure adequate vagal engagement in individual patients
Conclusion
Vagus nerve stimulation for heart failure represents a scientifically well-grounded approach to addressing a fundamental aspect of the disease — autonomic dysfunction. The rationale is supported by robust preclinical evidence and confirmed by the physiological effects observed in clinical trials. However, the clinical trial landscape has been mixed, with the positive signals from ANTHEM-HF tempered by the negative primary endpoints of INOVATE-HF and NECTAR-HF.
The emerging consensus is that the concept of VNS for heart failure is sound, but that achieving a sufficient "dose" of vagal activation is critical — and that earlier trials may have failed to cross this threshold. The next generation of trials, designed with this understanding, will determine whether VNS can join the established therapies for heart failure.
For clinicians and patients, the key message is that VNS for heart failure remains investigational. It should not be considered as a substitute for guideline-directed medical therapy, which remains the foundation of heart failure management. However, for a condition that continues to carry significant morbidity and mortality despite optimal treatment, the prospect of a therapy that addresses the autonomic and inflammatory dimensions of the disease warrants continued rigorous investigation.
---
References
De Ferrari, G.M. & Bhatt, D.L. (2017). Vagal stimulation in heart failure: where do we stand? European Heart Journal, 38(12), 907–909.
De Ferrari, G.M. et al. (2017). Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure. European Heart Journal, 32(7), 847–855.
Gold, M.R. et al. (2016). Vagus nerve stimulation for the treatment of heart failure: the INOVATE-HF trial. Journal of the American College of Cardiology, 68(2), 149–158.
Hamann, J.J. et al. (2013). Vagus nerve stimulation improves left ventricular function in a canine model of chronic heart failure. European Journal of Heart Failure, 15(12), 1319–1326.
Li, M. et al. (2004). Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation, 109(1), 120–124.
Nolan, J. et al. (1998). Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation, 98(15), 1510–1516.
Premchand, R.K. et al. (2014). Autonomic regulation therapy via left or right cervical vagus nerve stimulation in patients with chronic heart failure: results of the ANTHEM-HF trial. Journal of Cardiac Failure, 20(11), 808–816.
Premchand, R.K. et al. (2016). Extended follow-up of patients with heart failure receiving autonomic regulation therapy in the ANTHEM-HF study. Journal of Cardiac Failure, 22(8), 639–642.
Savarese, G. & Lund, L.H. (2017). Global public health burden of heart failure. Cardiac Failure Review, 3(1), 7–11.
Stavrakis, S. et al. (2015). Low-level transcutaneous electrical vagus nerve stimulation suppresses atrial fibrillation. Journal of the American College of Cardiology, 65(9), 867–875.
Tracey, K.J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859.
Wang, Y. et al. (2019). Low-level transcutaneous vagus nerve stimulation in patients with heart failure with preserved ejection fraction. Heart Rhythm, 16(5), S376.
Zannad, F. et al. (2015). Chronic vagal stimulation for the treatment of low ejection fraction heart failure: results of the Neural Cardiac Therapy for Heart Failure (NECTAR-HF) randomized controlled trial. European Heart Journal, 36(7), 425–433.
Zhang, Y. et al. (2009). Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circulation: Heart Failure, 2(6), 692–699.
Zhou, L. et al. (2022). Non-invasive vagus nerve stimulation for cardiovascular diseases: a systematic review. Heart Rhythm, 19(8), 1362–1370.
